ORIC Pharmaceuticals与Cancer Research UK达成协议，推进潜在first-in-class CIP2A靶向疗法ORIC-259进入临床开发

ORIC Pharmaceuticals与Cancer Research UK达成协议，由后者旗下Centre for Drug Development全额资助、申办、设计并执行ORIC-259的CTA enabling研究及I/II期临床开发。